May 2023

  • All
  • --
  • ---
  • -2022
  • 2022-2
  • 2022-2-2-2
  • 2022-deltia-tipoy
  • 2022-deltia-tipoy-2-2
  • 2022-deltia-tipoy-2-2-2-2
  • 2023-deltia-typou
  • 2023-deltia-typou-2-2
  • 2024
  • 257-2
  • 257-2-2-2
  • 266-2
  • Announcements
  • Consolidated Financial Results
  • deltia-tipoy
  • deltia-tipoy-2-2
  • deltia-tipoy-2-2-2-2
  • Distribution of Divident
  • Events
  • FAQ
  • General Meetings and Corporate Actions
  • Insiders Transactions Disclosures
  • Invitations
  • invitations-2
  • Presentations
  • Press Kits
  • Press Releases
  • Regulated Information
  • Results 2024
  • Share Capital Increase
  • Uncategorized

Η Ανώνυμη Εμπορική και Βιομηχανική Εταιρεία Φαρμακευτικών Χημικών και Καλλυντικών προϊόντων Lavipharm AE ανακοινώνει ότι την 26η Μαΐου 2023 πραγματοποιήθηκε η Έκτακτη Γενική Συνέλευση των Μετόχων της Εταιρείας στην έδρα της στο Δήμο Παιανίας Αττικής, οδός Αγίας Μαρίνας αρ. 12, όπου παρέστησαν Aποφάσεις της Έκτακτης Γενικής...

Vicky D. Kefalas joins Lavipharm’s Board of Directors Establishment of a long-term incentive plan Peania, 26 May 2023 – Lavipharm’s Extraordinary Shareholders Meeting, held at today at the corporate headquarters, decided in favor of the election of a new member of the Board of Directors and the...

Peania, 16 May 2023 – Lavipharm today presented its key financial results and activities to the Hellenic Fund and Asset Management Association. The presentation took place in the context of the Annual Analyst Update as per the Company’s 2023 Financial Calendar and was held at...

Paiania, 12 May 2023 – Lavipharm S.A., according to the provisions of article 19 of the European Regulation No 596/2014 and following relevant notification, announces that Mr. Thomas Tseronis, Head of Sales Rx, sold 35.434 Lavipharm common shares, amounting in total to €15.732,7....

Paiania, 4 May 2023 – Group Earnings before Interest, Tax, Depreciation and Amortization (EBITDA) increased by 34% during the first quarter of 2023 and amounted to €2.46 million compared to €1.84 million during the relevant period of the previous year. Lavipharm Key Financial Figues Q1 2023...